{"id":564061,"date":"2021-09-17T14:14:02","date_gmt":"2021-09-17T14:14:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=564061"},"modified":"2021-09-17T14:14:02","modified_gmt":"2021-09-17T14:14:02","slug":"chemotherapyinduced-diarrhea-pipeline-expected-to-witness-the-entry-of-novel-therapies-in-the-coming-decade-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-diarrhea-pipeline-expected-to-witness-the-entry-of-novel-therapies-in-the-coming-decade-delveinsight_564061.html","title":{"rendered":"Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631865337.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight \" src=\"https:\/\/www.abnewswire.com\/uploads\/1631865337.jpeg\" alt=\"Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chemotherapy-Induced Diarrhea Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;<strong>&#8216;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-diarrhea-pipeline-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Chemotherapy-induced Diarrhea Pipeline Insights<\/a>&#8216;<\/strong>&nbsp;report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Chemotherapy-induced Diarrhea Pipeline report provides a comprehensive view of the clinical trials, partnerships and collaborations, recent happenings in the space and growth prospects across the Chemotherapy-induced Diarrhea domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-diarrhea-pipeline-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Chemotherapy-induced Diarrhea Pipeline<\/a>&nbsp;report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Chemotherapy-induced Diarrhea Pipeline report offers a rich analysis of 5+ key players and 5+ key therapies.<\/li>\n<li>Chemotherapy-induced Diarrhea pipeline comprises emerging therapies in different stages of the clinical phase such as FW-420<strong>, Mytesi, OQL051, DP 1038&nbsp;<\/strong>and others.&nbsp;<\/li>\n<li>Some of the key companies working to strengthen the Chemotherapy-induced Diarrhea Pipeline are&nbsp;<strong>AzuRx BioPharma, Napo Pharmaceuticals, OnQuality Pharmaceuticals, Dauntless Pharmaceuticals,<\/strong>&nbsp;among others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample report to discover more about the therapies set to grab maximum patient pool @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-diarrhea-pipeline-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-diarrhea-pipeline-insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Chemotherapy-induced Diarrhea (CID) is a side-effect of frequently used chemotherapy agents and can lead to delays in treatment and poor quality of life. It is a common problem, especially in patients with advanced cancer and is most often described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-diarrhea-pipeline-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chemotherapy-induced Diarrhea Pipeline Drugs<\/a> Immunostimulants<\/strong><\/p>\n<table style=\"width: 603px;\" border=\"1\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p align=\"center\"><strong>Drug<\/strong><\/p>\n<\/td>\n<td>\n<p align=\"center\"><strong>Company<\/strong><\/p>\n<\/td>\n<td>\n<p align=\"center\"><strong>Phase<\/strong><\/p>\n<\/td>\n<td>\n<p align=\"center\"><strong>MoA<\/strong><\/p>\n<\/td>\n<td>\n<p align=\"center\"><strong>RoA<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>FW-420<\/strong><\/p>\n<\/td>\n<td>\n<p>AzuRx BioPharma<\/p>\n<\/td>\n<td>\n<p>Unknown<\/p>\n<\/td>\n<td>\n<p>MTOR protein inhibitors<\/p>\n<\/td>\n<td>\n<p>Oral\/rectal<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>Mytesi<\/strong><\/p>\n<\/td>\n<td>\n<p>Napo Pharmaceuticals<\/p>\n<\/td>\n<td>\n<p>Phase III<\/p>\n<\/td>\n<td>\n<p>Chloride channel antagonists<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>OQL051<\/strong><\/p>\n<\/td>\n<td>\n<p>OnQuality Pharmaceuticals<\/p>\n<\/td>\n<td>\n<p>Discovery<\/p>\n<\/td>\n<td>\n<p>NA<\/p>\n<\/td>\n<td>\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>DP 1038<\/strong><\/p>\n<\/td>\n<td>\n<p>Dauntless Pharmaceuticals<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Growth hormone-releasing hormone inhibitors;<\/p>\n<p>Somatostatin receptor agonists<\/p>\n<\/td>\n<td>\n<p>Intranasal<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy-induced Diarrhea Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The Chemotherapy-induced Diarrhea Pipeline report lays down complete insights into active Chemotherapy-induced Diarrhea pipeline therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong> <strong>Coverage<\/strong>: Global <strong>Key Players<\/strong>: AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals and others.&nbsp; <strong>Key Chemotherapy-induced Diarrhea Pipeline Therapies<\/strong>: FW-420, Mytesi, DP 1038, OQL051 and others.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Reach out @&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-diarrhea-pipeline-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-diarrhea-pipeline-insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table border=\"1\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p><strong>1<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>2<\/strong><\/p>\n<\/td>\n<td>\n<p>Chemotherapy-induced Diarrhea Disease Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>3<\/strong><\/p>\n<\/td>\n<td>\n<p>Chemotherapy-induced Diarrhea Pipeline Outlook<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>4<\/strong><\/p>\n<\/td>\n<td>\n<p>Comparative Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>5<\/strong><\/p>\n<\/td>\n<td>\n<p>Chemotherapy-induced Diarrhea Therapeutic Products in Clinical Stage<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>6<\/strong><\/p>\n<\/td>\n<td>\n<p>Chemotherapy-induced Diarrhea Therapeutic Products in Non-clinical Stage<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>7<\/strong><\/p>\n<\/td>\n<td>\n<p>Chemotherapy-induced Diarrhea Therapeutics Pipeline Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>8<\/strong><\/p>\n<\/td>\n<td>\n<p>Inactive Chemotherapy-induced Diarrhea Pipeline Products&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>9<\/strong><\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>10<\/strong><\/p>\n<\/td>\n<td>\n<p>Report Methodology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>11<\/strong><\/p>\n<\/td>\n<td>\n<p>Consulting Services<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>12<\/strong><\/p>\n<\/td>\n<td>\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>13<\/strong><\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">Visit to know more of what&#8217;s covered @&nbsp;<strong>https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-diarrhea-pipeline-insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p style=\"text-align: justify;\">Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform&nbsp;<strong>PharmDelve<\/strong>.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chemotherapyinduced-diarrhea-pipeline-expected-to-witness-the-entry-of-novel-therapies-in-the-coming-decade-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-diarrhea-pipeline-insights\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-diarrhea-pipeline-insights<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-diarrhea-pipeline-insights\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chemotherapyinduced-diarrhea-pipeline-expected-to-witness-the-entry-of-novel-therapies-in-the-coming-decade-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chemotherapy-Induced Diarrhea Pipeline DelveInsight&#8217;s&nbsp;&#8216;Chemotherapy-induced Diarrhea Pipeline Insights&#8216;&nbsp;report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.&nbsp; The Chemotherapy-induced Diarrhea Pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-diarrhea-pipeline-expected-to-witness-the-entry-of-novel-therapies-in-the-coming-decade-delveinsight_564061.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-564061","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=564061"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564061\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=564061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=564061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=564061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}